Price Increases Accounted For Over Half Of Drug Spending Growth In 2015
Executive Summary
CMS National Health Expenditures report finds continued double-digit growth rates for retail prescription drug spending in Medicare and Medicaid.
You may also be interested in...
Trump Win Is False Security For Drug Makers, Allergan CEO Warns
Industry should act on drug pricing now while there is a post-election reprieve, Allergan CEO Brent Saunders said during the Forbes Healthcare Summit. Trump is a populist who will jump on the next big pricing scandal, he said.
Part D Reform Proposals From MedPAC May Find Traction After Election
Advisory group’s cost control recommendations on reinsurance, partial fills, and preferred specialty tiers could end up on the legislative agenda, particularly if Hillary Clinton is president.
Medicaid Rx Spending Up 24% in 2014 With Expanded Eligibility, HCV Drugs
HCV drugs also contribute to 16.9% surge in Medicare Part D spending in 2014, CMS says in health expenditures review.